Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RMC-5552 (Primary)
  • Indications Head and neck cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors REVOLUTION Medicines

    • Most Recent Events

    • 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2023 According to a REVOLUTION Medicines media release, data from this study will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Triple Meeting) in Boston, Massachusetts, to be held October 11-15, and the 2023 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, to be held October 20-24.
    • 08 May 2023 According to an REVOLUTION Medicines media release, the company is anticipates disclosing additional evidence of single agent activity for this compound in Q4 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top